CARPETS: A Phase I Open Label Study of the Safety and Immune effects of an Escalating Dose of Autologous GD2 Chimeric Antigen Receptor-Expressing Peripheral Blood T Cells in Patients with Metastatic BRAF-Mutant and GD2-Positive Melanoma

恶性黑色素瘤在澳大利亚的发病率正在上升。目前治疗晚期黑色素瘤的药物仅在某些时候有效。具有抗黑色素瘤活性的BRAF阻断药物正在澳大利亚进行测试，但耐药性正在发展。我们将对病人自身的T细胞进行基因改造，使其重新定向以对抗黑素瘤。该方法的可行性、安全性和免疫效果将在晚期黑色素瘤对BRAF阻滞剂不再有反应的患者中进行测试。

Malignant melanoma is increasing in incidence in Australia. Current drugs for advanced melanoma are only sometimes effective. BRAF blocking drugs with promising anti-melanoma activity are being tested in Australia but drug resistance is developing. We will genetically engineer the patient’s own T cells to redirect them against the melanoma. The feasibility, safety, and immune effects of this approach will be tested in patients whose advanced melanoma is no longer responding to BRAF blockers.